Respironics Awakens In April; Strong Sales Spark 13% Stock Price Gain

Respironics' third-quarter results awakened Wall Street to the fact that the sleep-disorder equipment manufacturer had shrugged off its recent reimbursement difficulties. The company's stock price was up 13%, or 1-7/8, in April, closing the month at 16-1/4.